Trial Profile

A Phase Ib, Multicenter Study of VOB560 in Combination With MIK665 in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 01 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs S 64315 (Primary) ; S 65487 (Primary)
Indications Acute myeloid leukaemia; Multiple myeloma; Non-Hodgkin's lymphoma
Focus Adverse reactions; First in man
Sponsors Novartis Pharmaceuticals

04 Sep 2024 Status changed from active, no longer recruiting to discontinued.
23 Jul 2024 Planned End Date changed from 30 Jul 2024 to 26 Jul 2024.
23 Jul 2024 Planned primary completion date changed from 30 Jul 2024 to 26 Jul 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com